Hussman Strategic Advisors Inc. Takes Position in ADMA Biologics Inc (NASDAQ:ADMA)

Hussman Strategic Advisors Inc. purchased a new position in ADMA Biologics Inc (NASDAQ:ADMA - Free Report) in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 105,000 shares of the biotechnology company's stock, valued at approximately $2,083,000.

A number of other institutional investors have also bought and sold shares of the business. JPMorgan Chase & Co. lifted its holdings in shares of ADMA Biologics by 272.5% in the 4th quarter. JPMorgan Chase & Co. now owns 767,265 shares of the biotechnology company's stock valued at $13,159,000 after acquiring an additional 561,310 shares during the last quarter. Sei Investments Co. lifted its stake in ADMA Biologics by 147.2% in the fourth quarter. Sei Investments Co. now owns 527,272 shares of the biotechnology company's stock worth $9,043,000 after purchasing an additional 314,013 shares during the last quarter. New York State Teachers Retirement System raised its stake in shares of ADMA Biologics by 96.2% during the first quarter. New York State Teachers Retirement System now owns 221,890 shares of the biotechnology company's stock valued at $4,402,000 after acquiring an additional 108,800 shares in the last quarter. Swiss National Bank raised its stake in shares of ADMA Biologics by 6.6% during the fourth quarter. Swiss National Bank now owns 458,400 shares of the biotechnology company's stock valued at $7,862,000 after acquiring an additional 28,500 shares in the last quarter. Finally, GAMMA Investing LLC raised its stake in shares of ADMA Biologics by 251.6% during the first quarter. GAMMA Investing LLC now owns 6,589 shares of the biotechnology company's stock valued at $131,000 after acquiring an additional 4,715 shares in the last quarter. Hedge funds and other institutional investors own 75.68% of the company's stock.

Insider Buying and Selling at ADMA Biologics

In related news, Director Lawrence P. Guiheen sold 20,000 shares of the company's stock in a transaction dated Monday, June 9th. The shares were sold at an average price of $20.96, for a total transaction of $419,200.00. Following the completion of the transaction, the director owned 94,830 shares in the company, valued at $1,987,636.80. This represents a 17.42% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Steve Elms sold 194,749 shares of the company's stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $20.24, for a total transaction of $3,941,719.76. Following the transaction, the director owned 87,330 shares of the company's stock, valued at approximately $1,767,559.20. This trade represents a 69.04% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 464,621 shares of company stock valued at $9,644,269. 3.50% of the stock is owned by insiders.

ADMA Biologics Stock Performance

Shares of ADMA traded down $0.86 during trading hours on Friday, reaching $16.73. 3,840,226 shares of the company traded hands, compared to its average volume of 3,655,902. The stock has a market capitalization of $3.99 billion, a P/E ratio of 19.68 and a beta of 0.43. The company has a quick ratio of 3.36, a current ratio of 6.58 and a debt-to-equity ratio of 0.22. ADMA Biologics Inc has a 12-month low of $10.21 and a 12-month high of $25.67. The business has a fifty day moving average price of $19.22 and a 200-day moving average price of $18.75.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported $0.14 earnings per share for the quarter, missing analysts' consensus estimates of $0.16 by ($0.02). The company had revenue of $114.80 million for the quarter, compared to analysts' expectations of $116.40 million. ADMA Biologics had a net margin of 45.01% and a return on equity of 47.16%. ADMA Biologics's quarterly revenue was up 40.2% compared to the same quarter last year. During the same period last year, the firm earned $0.08 earnings per share. Equities analysts anticipate that ADMA Biologics Inc will post 0.51 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the stock. Wall Street Zen downgraded shares of ADMA Biologics from a "hold" rating to a "sell" rating in a research note on Friday, May 9th. Raymond James Financial lifted their price target on shares of ADMA Biologics from $25.00 to $32.00 and gave the company a "strong-buy" rating in a research note on Thursday, May 8th.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.